Trials / Terminated
TerminatedNCT02207309
Pazopanib Maintenance Phase II
A Randomized, Double Blind, Phase II Trial of Pazopanib Versus Placebo as Maintenance Therapy in Patients With Retroperitoneal and Visceral High-risk Soft Tissue Sarcomas Following Prior Neo- and/or Adjuvant Doxorubicin / Ifosfamide Chemotherapy With Regional Hyperthermia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Ludwig-Maximilians - University of Munich · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial compares pazopanib to placebo as maintenance treatment over 2 years in patients with retroperitoneal and visceral high-risk soft tissue sarcomas after multimodal treatment including prior neo- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional hyperthermia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib | |
| DRUG | Placebo (for Pazopanib) |
Timeline
- Start date
- 2015-06-22
- Primary completion
- 2016-07-29
- Completion
- 2016-07-29
- First posted
- 2014-08-04
- Last updated
- 2024-08-09
- Results posted
- 2024-08-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02207309. Inclusion in this directory is not an endorsement.